Company Registration No. 08379504 (England and Wales)
HEALTH ELIXIR LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
Vivian House
Newham Road
Truro
Cornwall
United Kingdom
TR1 2DP
HEALTH ELIXIR LIMITED
CONTENTS
Page
Company information
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
HEALTH ELIXIR LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
34,614
49,999
Tangible assets
4
14,012
9,588
48,626
59,587
Current assets
Stocks
25,661
27,108
Debtors
5
49,956
45,476
Cash at bank and in hand
207,124
222,933
282,741
295,517
Creditors: amounts falling due within one year
6
(110,538)
(98,783)
Net current assets
172,203
196,734
Total assets less current liabilities
220,829
256,321
Provisions for liabilities
(2,662)
(2,397)
Net assets
218,167
253,924
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
218,165
253,922
Total equity
218,167
253,924
HEALTH ELIXIR LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JANUARY 2026
31 January 2026
- 2 -

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 15 May 2026
Mr F Baig
Director
Company registration number 08379504 (England and Wales)
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 3 -
1
Accounting policies
Company information

Health Elixir Limited is a private company limited by shares incorporated in England and Wales. The registered office is 12 Kings Road, St Mawes, TRURO, Cornwall, England, TR 2 5DH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

The company's ability to continue trading is dependent upon the continued support of its creditors and antrue improvement in the company's trading results. On the assumption that the support is ongoing the director considers that it is appropriate to prepare the financial statements on the going concern basis. The financial statements do not include any adjustments that would result if the bank was to withdraw its support or if trading results do not improve.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 4 -
1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 13 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% on cost
Fixtures and fittings
15% on cost
Computers
20% on cost
Motor vehicles
15% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 5 -
1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Retirement benefits

The cost of providing benefits under defined benefit plans is determined separately for each plan using the projected unit credit method, and is based on actuarial advice.

 

The change in the net defined benefit liability arising from employee service during the year is recognised as an employee cost. The cost of plan introductions, benefit changes, settlements and curtailments are recognised as an expense in measuring profit or loss in the period in which they arise.

1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 6 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
4
4
3
Intangible fixed assets
Total
£
Cost
At 1 February 2025 and 31 January 2026
200,000
Amortisation and impairment
At 1 February 2025
150,001
Amortisation charged for the year
15,385
At 31 January 2026
165,386
Carrying amount
At 31 January 2026
34,614
At 31 January 2025
49,999
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 7 -
4
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 February 2025
1,901
27,662
5,918
-
0
35,481
Additions
-
0
-
0
-
0
9,500
9,500
At 31 January 2026
1,901
27,662
5,918
9,500
44,981
Depreciation and impairment
At 1 February 2025
1,358
19,618
4,917
-
0
25,893
Depreciation charged in the year
359
2,925
367
1,425
5,076
At 31 January 2026
1,717
22,543
5,284
1,425
30,969
Carrying amount
At 31 January 2026
184
5,119
634
8,075
14,012
At 31 January 2025
543
8,044
1,001
-
0
9,588
5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
560
1,515
Other debtors
5,783
6,498
Prepayments and accrued income
43,613
37,463
49,956
45,476
6
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
27,706
20,230
Corporation tax
1,807
19,374
Other taxation and social security
10,476
816
Other creditors
67,452
55,402
Accruals and deferred income
3,097
2,961
110,538
98,783
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 8 -
7
Ultimate controlling party

The ultimate controlling party is Mr F Baig.

2026-01-312025-02-01falsefalsefalse15 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr Faisel Baig083795042025-02-012026-01-31083795042026-01-31083795042025-01-3108379504core:PlantMachinery2026-01-3108379504core:FurnitureFittings2026-01-3108379504core:ComputerEquipment2026-01-3108379504core:MotorVehicles2026-01-3108379504core:PlantMachinery2025-01-3108379504core:FurnitureFittings2025-01-3108379504core:ComputerEquipment2025-01-3108379504core:MotorVehicles2025-01-3108379504core:CurrentFinancialInstrumentscore:WithinOneYear2026-01-3108379504core:CurrentFinancialInstrumentscore:WithinOneYear2025-01-3108379504core:ShareCapital2026-01-3108379504core:ShareCapital2025-01-3108379504core:RetainedEarningsAccumulatedLosses2026-01-3108379504core:RetainedEarningsAccumulatedLosses2025-01-3108379504bus:Director12025-02-012026-01-3108379504core:Goodwill2025-02-012026-01-3108379504core:PlantMachinery2025-02-012026-01-3108379504core:FurnitureFittings2025-02-012026-01-3108379504core:ComputerEquipment2025-02-012026-01-3108379504core:MotorVehicles2025-02-012026-01-31083795042024-02-012025-01-31083795042025-01-3108379504core:PlantMachinery2025-01-3108379504core:FurnitureFittings2025-01-3108379504core:ComputerEquipment2025-01-3108379504core:MotorVehicles2025-01-3108379504core:CurrentFinancialInstruments2026-01-3108379504core:CurrentFinancialInstruments2025-01-3108379504bus:PrivateLimitedCompanyLtd2025-02-012026-01-3108379504bus:SmallCompaniesRegimeForAccounts2025-02-012026-01-3108379504bus:FRS1022025-02-012026-01-3108379504bus:AuditExemptWithAccountantsReport2025-02-012026-01-3108379504bus:FullAccounts2025-02-012026-01-31xbrli:purexbrli:sharesiso4217:GBP